Sartorius Stedim Biotech (SSB) has opened a bioanalytical and biosafety testing laboratory in the major biotech hub of Boston, Massachusetts.
The dedicated bioanalytical facility is designed to accommodate the rising demand for the company’s BioOutsource brand specialised assay platforms in North America, and facilitate the ongoing expansion of its service offering.
Reinhardt Vogt, member of SSB’s Executive Committee, said: “Our new laboratory will offer customers the analytical expertise to help them accelerate entry into clinical phases. We chose Boston as the site for our laboratory because it is a premier biotech hub, enabling us to showcase our portfolio of bioanalytical and biosafety tests, as well as attract the best technical staff to continue our expansion here in the future.”
The purpose-built laboratory features state-of-the-art technology, such as biacore analytical instruments. It will also offer advanced analytical testing services such as Antibody Dependent Cell Cytotoxicity (ADCC), Complement Dependent Cytotoxicity (CDC) and Surface Plasmon Resonance (SPR) assay platforms, as well as cell-based assays and enzyme-linked immunosorbent assays (ELISAs).
The facility, which covers approximately 9,000 sq. ft. (830 m2), will also provide GMP-compliant in vitro and PCR-based assays for the detection of adventitious agents. It is staffed by bioanalytical experts, including 15 scientists, and offers easy access for customers to visit and have face-to-face meetings to discuss technical questions.
